Home LiteratureArticle Details
PMID: 16385253 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Eradication of small intestinal bacterial overgrowth in the cystic fibrosis mouse reduces mucus accumulation.

Journal of pediatric gastroenterology and nutrition ·Vol. 42 ·No. 1 ·2006-01-00 ·Pages 46-52

De Lisle RC, Roach EA, Norkina O

Abstract

Mucus accumulation in cystic fibrosis (CF) is involved in blockage of the distal small intestine. Because expression of mucin genes and mucus secretion can be increased by infection and previous work indicated that small intestinal bacterial overgrowth occurs in CF, we tested whether reduction of bacterial load by antibiotic treatment would reduce mucin gene expression and mucus accumulation in the CF mouse small intestine. CF transmembrane conductance regulator null (cftr (tm1UNC)) and wild type littermates were treated with ciprofloxacin and metronidazole for 3 weeks. Muc2 and Muc3 gene expression were measured by quantitative reverse-transcriptase polymerase chain reaction. Periodic acid Schiff (PAS) staining and morphometry were used to measure the size of mucus droplets within goblet cells and dilation of the intestinal crypt lumen, as estimates of mucus secretion and accumulation. Antibiotic treatment did not significantly affect Muc2 and Muc3 gene expression in CF mice. In untreated CF mice, the crypt lumen was almost sevenfold wider than wild type. Antibiotic treatment of CF mice reduced the intensity of PAS crypt lumen staining, and the lumen width was decreased by approximately 25%. The area occupied by PAS-positive material in goblet cells was significantly greater in tissues from antibiotic treated mice. Eradication of bacterial overgrowth in CF mice significantly decreased mucus secretion and accumulation in intestinal crypts without an effect on mucin gene expression. It is proposed that bacterial overgrowth stimulates mucus secretion, which contributes to its accumulation in the small intestine. Control of bacterial overgrowth is expected to reduce mucus accumulation and may improve intestinal function and overall health in CF.

MeSH Terms
Animals Anti-Infective Agents/pharmacology Bacteria/drug effects,growth & development Ciprofloxacin/pharmacology Cystic Fibrosis/physiopathology Cystic Fibrosis Transmembrane Conductance Regulator Disease Models, Animal Female Intestine, Small/microbiology,pathology Male Metronidazole/pharmacology Mice Mice, Inbred C57BL Mice, Inbred CFTR Mucins/genetics,metabolism Mucus/metabolism Periodic Acid-Schiff Reaction Reverse Transcriptase Polymerase Chain Reaction
Chemicals
Anti-Infective Agents Mucins Cystic Fibrosis Transmembrane Conductance Regulator Metronidazole Ciprofloxacin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
De Lisle Robert C
Anatomy and Cell Biology, University of Kansas School of Medicine, Kansas City, Kansas 66160, USA. rdelisle@kumc.edu
Roach Eileen A
Norkina Oxana
Article Info
Journal
Journal of pediatric gastroenterology and nutrition
Abbr.
J Pediatr Gastroenterol Nutr
ISSN
0277-2116
Published
2006-01-00
Pages
46-52
Language
English
Region
United States
NLM ID
8211545
Subset
IM
Grants
NIDDK NIH HHS · R01 DK056791-01 · United States
NIDDK NIH HHS · R01 DK056791-04 · United States
NIDDK NIH HHS · DK56791 · United States
NIDDK NIH HHS · R01 DK056791-03 · United States
NIDDK NIH HHS · R01 DK056791 · United States
NIDDK NIH HHS · R01 DK056791-02 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com